Introduction {#section1-1076029619840701}
============

Heparin is a critically important anticoagulant--antithrombotic drug without which the practice of modern medicine would not be possible.^[@bibr1-1076029619840701]^ Heparin, a natural product, is extracted in ton quantities from the tissues of food animals.^[@bibr2-1076029619840701]^ Porcine intestinal tissue is the principal source of heparin worldwide.^[@bibr2-1076029619840701],[@bibr3-1076029619840701]^ The worldwide dependence on the pig as a single dominant animal species has made the supply chain for this critical drug quite fragile, leading to the search for other sources of these drugs, including the expanded use of bovine tissues.^[@bibr4-1076029619840701]^ Moreover, the production of bioengineered heparins prepared through a combination of microbial fermentation and chemoenzymatic synthesis^[@bibr5-1076029619840701]^ or using metabolic engineering^[@bibr6-1076029619840701]^ is now under extensive study.

This reexamination of the sourcing of heparin is largely motivated by the 2007 to 2008 heparin contamination crisis in which much of the world's supply of porcine intestinal heparin was adulterated with oversulfated chondroitin sulfate. Oversulfated chondroitin sulfate resulted in the biochemical activation of multiple pathways in the circulation leading to hypotension and death of a number of patients receiving contaminated heparin.^[@bibr7-1076029619840701],[@bibr8-1076029619840701]^ This crisis resulted in the introduction of new analytical methodology for heparin^[@bibr9-1076029619840701][@bibr10-1076029619840701][@bibr11-1076029619840701][@bibr12-1076029619840701][@bibr13-1076029619840701][@bibr14-1076029619840701][@bibr15-1076029619840701][@bibr16-1076029619840701]-[@bibr17-1076029619840701]^ as well as revised, more rigorous pharmacopeial monographs for this class of drugs.^[@bibr18-1076029619840701]^

Heparin is a linear, polydisperse, microheterogenous, polysaccharide comprised repeating disaccharide units of α-[l]{.smallcaps}-iduronic (IdoA) or β-[d]{.smallcaps}-glucuronic acid (GlcA) 1,4-glycosidically linked to α-[d]{.smallcaps}-glucosamine residues (GlcN) selectively modified with *O*- and *N*-sulfo (S) and *N*-acetyl (Ac) groups ([Table 1](#table1-1076029619840701){ref-type="table"}).^[@bibr3-1076029619840701]^ This polycomponent agent has a very complex structure and exhibits multiple biological and pharmacological activities. Heparin produced from animal tissues, referred to as unfractionated heparin, is primarily used as an intravenous agent with a relatively short half-life.^[@bibr19-1076029619840701]^ Low-molecular-weight heparins (LMWHs), derived from unfractionated heparin through its controlled chemical or enzymatic depolymerization, are subcutaneously active and display significantly longer half-lives.^[@bibr19-1076029619840701]^ The most widely used LMWH, enoxaparin, is prepared from unfractionated heparin through a controlled chemical β-elimination reaction.^[@bibr20-1076029619840701]^ This chemistry reduces both the average molecular weight (MW) of heparin from approximately 18 000 Da to approximately 4000 Da and introduces certain structural artifacts, an unsaturated uronic acid residue (ΔUA) and 1,6-anhydrosugar residues (1,6-AnH), into some of the polysaccharide chains of the resulting LMWH. These constitute signature structures of the enoxaparin product which are referred to in the enoxaparin monograph.^[@bibr21-1076029619840701]^

###### 

Preparation of Low-Molecular-Weight Heparin Analog of Enoxaparin From Ovine Heparins.
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In a previous study, we examined the use of bovine intestinal heparin to prepare a bovine enoxaparin product using a controlled chemical β-elimination reaction.^[@bibr15-1076029619840701],[@bibr22-1076029619840701]^ Worldwide there are 1.4 billion cattle, 1.9 billion sheep and goats, and 980 million pigs.^[@bibr23-1076029619840701]^ Sheep might provide alternate source of heparin in the form of ovine intestinal heparin. Ovine intestinal heparin has been used in the past to produce unfractionated heparin and has recently been suggested as a source for the production of LMWHs, such as enoxaparin.^[@bibr10-1076029619840701],[@bibr23-1076029619840701][@bibr24-1076029619840701]-[@bibr25-1076029619840701]^ In the current study, we have prepared 3 batches of unfractionated heparin from ovine intestine. These batches were then used to prepare 3 batches of ovine enoxaparin ([Table 1](#table1-1076029619840701){ref-type="table"}). These ovine-derived heparin products were chemically analyzed using state-of-the-art methods and their biological/pharmacological activities were evaluated. The structure and activity of unfractionated ovine intestinal heparin and ovine enoxaparin were compared to the porcine-derived products.

Materials and Methods {#section2-1076029619840701}
=====================

Materials {#section3-1076029619840701}
---------

The ovine heparins and ovine-derived LMWHs were obtained from Ronnsi (Jiangsu, China). Porcine intestinal heparin reference standard was obtained from the US Pharmacopeial Convention (USP). Lovenox from Sanofi-Aventis (Bridgewater, New Jersey) was obtained from commercial suppliers. All samples were analyzed prior to their expiration dates. Heparin disaccharide standards (0S: ΔUA \[1 → 4\] GlcNAc; NS: ΔUA \[1 → 4\] GlcNS; 6S: ΔUA \[1 → 4\] GlcNAc6S; 2S: ΔUA2S \[1 → 4\] GlcNAc; NS2S: ΔUA2S \[1 → 4\] GlcNS; NS6S: ΔUA \[1 → 4\] GlcNS6S; 2S6S: ΔUA2S \[1 → 4\] GlcNAc6S; and TriS: ΔUA2S \[1 → 4\] GlcNS6S, where ΔUA is 4-deoxy-β-[l]{.smallcaps}-threo-hex-4-enopyranosiduronic acid, GlcN is glucosamine, Ac is acetyl, and S is sulfo) were from Iduron (Manchester, United Kingdom). Tributylamine was from Sigma Chemical (St Louis, Missouri). Ammonium acetate, calcium chloride, acetic acid, water, and acetonitrile were of high-performance liquid chromatography grade (Fisher Scientific, Springfield, New Jersey). Microcon YM-3 centrifugal filter units were obtained from Millipore (Bedford, Massachusetts). *Escherichia coli* expression and purification of recombinant flavobacterial heparin lyase I, II, and III (Enzyme Commission \#s 4.2.2.7, 4.2.2.X, and 4.2.2.8) were performed in our laboratory as described previously.^[@bibr26-1076029619840701]^ The LMWHs were desalted by dialysis using 1-kDa MW cutoff dialysis tube (Spectrum Laboratories, Rancho Dominguez, California), lyophilized before NMR analysis, and redissolved in distilled water into stock solution (20 mg/mL) for liquid chromatography (LC)-mass spectrometry (MS) analysis.

Chemical β-Elimination of Ovine Heparin {#section4-1076029619840701}
---------------------------------------

Chemical β-elimination of porcine and ovine heparins to prepare LMWHs has been described in detail previously.^[@bibr2-1076029619840701]^ Sodium heparin was converted into benzethonium salt and was recovered by precipitation. The heparin benzethonium salt was dissolved in methylene chloride and benzylated using benzyl chloride. The benzyl ester of ovine heparin was recovered and treated with aqueous sodium hydroxide resulting in its alkaline depolymerization and debenzylation. Recovery by methanol precipitation and dialysis provided the ovine enoxaparin.

Potency Evaluation {#section5-1076029619840701}
------------------

Ovine heparin and enoxaparin were supplemented in pooled normal human plasma and tested in a concentration range of 0 to 10 μg/mL to determine potency. The amidolytic anti-IIa and anti-Xa assays were performed on an ACL ELITE (Instrumentation Laboratory, Lexington, Massachusetts) using bovine Xa and human thrombin (TH) from Enzyme Research Laboratories (South Bend, Indiana). Chromogenic substrates, Spectrozyme Xa, and TH were obtained from American Diagnostica (Stamford, Connecticut) or using kits from Aniara Diagnostica (West Chester, Ohio). The potency of the ovine heparin was calculated using the USP standard for heparin (lot FOI 187). The potency of each heparin was calculated based on the calibration curve prepared with the USP heparin standard. The potency of the enoxaparin was calculated using the National Institute for Biological Standards and Control (01/608; Potters Bar, England) standard.

Activity and MW Assays {#section6-1076029619840701}
----------------------

The activity and MW assays for heparins and LMWHs were comparable to USP methods.^[@bibr27-1076029619840701]^

Disaccharide Analysis {#section7-1076029619840701}
---------------------

Each sample (100 μg) was dissolved in 100 μL digestion buffer (50 mmol/L NH~4~OAc, 2 mmol/L CaCl~2~, pH 7.0). A mixture of heparin lyase I, II, and III (10 mU each in Tris--HCl buffer, pH 7.0) was added and the samples were digested in 37°C water bath for 12 hours. The lyase enzymes were removed using a YM-3 centrifugal filter unit (Millipore, Billerica, Massachusetts) to terminate the reaction. The filtrates were lyophilized and redissolved in distilled water at a concentration of 1 mg/mL. Reversed-phase, ion-pairing LC with online electrospray ion (ESI)-trap MS analysis relied on an Agilent 1200 LC/MSD instrument (Agilent Technologies, Wilmington, Delaware) equipped with a 6300 ion-trap and a binary pump. A solution of disaccharide standards was prepared (each disaccharide at 100 μg/μL) for relative quantification.

Bottom-Up Analysis of Heparins and LMWHs {#section8-1076029619840701}
----------------------------------------

Each sample (100 μg) was added to 100 μL digestion buffer (50 mmol/L pH 7.0). Heparin lyase II (10 mU in Tris--HCl buffer, pH 7.0) was added and the sample was digested in 37°C water bath for 12 hours to produce fragments. Enzymatic digestion was terminated by removing the enzymes using an YM-3 centrifugal filter unit. The filtrates were lyophilized and redissolved in 100 µL of distilled water at a concentration of 1 µg/mL. Online hydrophilic interaction chromatography (HILIC) Fourier transform mass spectrometry (FTMS) was used to analyze the resulting oligosaccharides.^[@bibr12-1076029619840701]^ A Luna HILIC column (2.0 mm^2^ × 50 mm^2^, 200 Å; Phenomenex, Torrance, California) was connected online to the standard ESI source of LTQ-Orbitrap XL FTMS (Thermo Fisher Scientific, San Jose, California). Mass spectra were acquired at a resolution 60 000 with 200 to 1800 *m/z* range.

Top-Down Analysis of LMWHs {#section9-1076029619840701}
--------------------------

Online HILIC-FTMS was applied to analyze the intact chains.^[@bibr13-1076029619840701]^ A Luna HILIC column (2.0 mm^2^ × 150 mm^2^, 200 Å; Phenomenex, Torrance, California) was used. Mass spectra were acquired at a resolution 60 000 with 200 to 2000 Da mass range.

Bioinformatics Used in Processing Bottom-Up and Top-Down Data {#section10-1076029619840701}
-------------------------------------------------------------

Charge deconvolution was autoprocessed by DeconTools software (web source from PNNL at <http://omics.pnl.gov/>). The LMWH structural assignment was done by automatic processing using GlycReSoft 1.0 software developed at Boston University (<http://code.google.com/p/glycresoft/downloads/list>).^[@bibr28-1076029619840701]^ A theoretical database was generated by GlycReSoft 1.0 as described previously.^[@bibr13-1076029619840701]^ All of the relative quantitative data were normalized to the total identified oligosaccharides peak area (in the format of percentage).

Nuclear Magnetic Resonance Analysis {#section11-1076029619840701}
-----------------------------------

One-dimensional (1D) ^1^H and ^13^C NMR spectra were obtained at 600 MHz on ^2^H~2~O exchanged heparin (20 mg/mL in ^2^H~2~O) using a Bruker Advance II 600 MHz spectrometer (Bruker BioSpin, Billerica, Massachusetts) with Topspin 3.2 software (Bruker BioSpin) for signal integration. Two-dimensional HSQC-NMR spectra were obtained at 800 MHz on ^2^H~2~O exchanged heparin (20 mg/mL in ^2^H~2~O) using a Bruker Advance II 800 MHz spectrometer.^[@bibr10-1076029619840701]^

Results and Discussion {#section12-1076029619840701}
======================

Three batches of ovine heparin were prepared from ovine intestinal mucosa ([Table 1](#table1-1076029619840701){ref-type="table"}). The MWs of the ovine heparins were somewhat lower than those for USP heparin produced from porcine intestine ([Table 2](#table2-1076029619840701){ref-type="table"}).

###### 

Molecular Weight and Potency of Ovine Heparin Sodium and Ovine Enoxaparin Sodium.

![](10.1177_1076029619840701-table2)

  Lot\#           Ovine Heparin Sodium   HP std   Ovine Enoxaparin Sodium   LMWH std                        
  --------------- ---------------------- -------- ------------------------- ---------- ------ ------ ------ ------
  MW (Da)                                                                                                   
   MW (UV)        13 624                 13 558   14 459                    18 853     3778   3761   3820   4026
   MW (RI)        13 407                 13 499   14 299                    18 856     4245   4192   4274   4486
   Mn (UV)        10 113                 10 025   10 772                    14 781     3260   3242   3311   3403
   Mn (RI)        9794                   9762     10 525                    15 405     3725   3686   3739   3823
  USP potency                                                                                               
   Xa (U/mg)      201                    196      205                       190        105    103    118    107
   IIa (U/mg)     201                    193      201                       191        42     41     43     39
   Xa/IIa ratio   1.00                   1.02     1.02                      0.99       2.5    2.5    2.7    2.7

Abbreviations: MW, molecular weight; RI, refractive index.

Characterization of the MW and Activity Properties {#section13-1076029619840701}
--------------------------------------------------

The USP porcine heparin had a weight average MW of 18 900 with a polydispersity index (PI) of 1.23, and the ovine heparins had an average MW of 13 800 and an average PI of 1.38. Each parent ovine heparin was then converted to their benzyl esters and chemically β-eliminated to afford 3 daughter ovine enoxaparins. The ovine enoxaparin had an average MW of 4200 and an average PI of 1.14 very similar to porcine enoxaparin MW of 4300 and a PI of 1.19 ([Table 2](#table2-1076029619840701){ref-type="table"} and SI 1-4). The anticoagulant activities, as determined using antifactor Xa and IIa assays, of unfractionated USP porcine heparin and ovine heparins and the porcine and ovine enoxaparins were very similar showing no major differences ([Table 2](#table2-1076029619840701){ref-type="table"} and SI 5-6).

Nuclear Magnetic Resonance Analysis {#section14-1076029619840701}
-----------------------------------

The NMR analysis of the unfractionated ovine and porcine heparins and the ovine and porcine enoxaparins was next undertaken. The 3 batches of parent ovine heparin and the 3 batches of daughter heparin were very similar to one another, indicating that the batch-to-batch variability of the ovine heparin preparation and ovine enoxaparin preparation was very low ([Figure 1](#fig1-1076029619840701){ref-type="fig"}).

![Composition by nuclear magnetic resonance (NMR) integration. The error bars indicate the analytical variability in the method.](10.1177_1076029619840701-fig1){#fig1-1076029619840701}

As anticipated, the parent unfractionated heparin differed from the daughter enoxaparins. The ovine parent heparins (OES-404A, 80-ALR-089, and 80-ALR-092) all showed higher GlcA content but lower GlcNY3S6X and IdoA2S content when compared to the daughter samples (OES-401D, OES-402D, and OES-403D). The ovine parent samples had a saccharide composition that was very similar to a standard USP porcine intestinal heparin.

Disaccharide Analysis {#section15-1076029619840701}
---------------------

Disaccharide analysis uses a cocktail of heparin lyase enzymes to convert either unfractionated heparin or LMWH to a mixture of disaccharides that are then determined by LC-MS analysis. The disaccharide compositional analysis of the parent ovine heparins, the daughter ovine enoxaparins, and porcine enoxaparin (Lovenox) was examined ([Figure 2](#fig2-1076029619840701){ref-type="fig"}). The disaccharide composition of 3 batches of parent heparins and their daughter LMWHs was similar and consistent with the NMR data as shown in [Figure 1](#fig1-1076029619840701){ref-type="fig"}. Interestingly, both the ovine heparin and ovine enoxaparin had a significantly higher percentage of Tris than did porcine enoxaparin, Lovenox, suggesting that ovine enoxaparins were richer in IdoA2S(1 → 4)GlcNS6S sequences.

![Disaccharide analysis by liquid chromatography mass spectrometry (LC-MS) presented by bar chart and pie chart.](10.1177_1076029619840701-fig2){#fig2-1076029619840701}

Top-Down Analysis {#section16-1076029619840701}
-----------------

Top-down analysis uses LC-MS to examine intact oligosaccharide chains found within an LMWH. The top-down analysis of LMWHs showed that ovine enoxaparin contains 227 oligosaccharide species ([Figure 3](#fig3-1076029619840701){ref-type="fig"}), while 225 oligosaccharide species were identified in Lovenox, and 130 of the same oligosaccharide species were present in both ovine enoxaparin and Lovenox ([Figure 4](#fig4-1076029619840701){ref-type="fig"}). The highly sulfated oligosaccharides, \[1, 2, 3, 0 8\], \[1, 4, 5, 0, 12\], \[1, 5, 6, 0, 16\], \[1, 5, 6, 0, 17\], and \[1, 6, 7, 0, 17\], in ovine enoxaparin were in higher abundance than in Lovenox. The less sulfated *N*-acetylated oligosaccharides, \[1, 4, 5, 1, 10\], \[1, 4, 5, 1, 11\], and \[1, 4, 5, 1, 12\], was in higher abundance in ovine enoxaparin than in Lovenox. These analyses were in agreement with the disaccharide analysis, showing that ovine enoxaparins were richer in IdoA2S(1 → 4)GlcNS6S sequences ([Figure 2](#fig2-1076029619840701){ref-type="fig"}).

![Top-down analysis of low-molecular-weight heparins (LMWHs). For the 3 ovine enoxaparin intact chains detected in top-down analysis whose (A) reducing ends are 1, 6-anhydro, (B) nonreducing ends are unsaturated, and (C) nonreducing ends are saturated. The error bars indicate sample variability.](10.1177_1076029619840701-fig3){#fig3-1076029619840701}

![Top-down analysis of low-molecular-weight heparins (LMWHs). Comparison of ovine enoxaparin and Lovenox about intact chains detected in top-down analysis whose (A) reducing ends are 1,6-anhydro, (B) nonreducing ends are unsaturated, and (C) nonreducing ends are saturated.](10.1177_1076029619840701-fig4){#fig4-1076029619840701}

Bottom-Up Analysis {#section17-1076029619840701}
------------------

Treatment of LMWH sample with a single heparin lyase, heparin lyase II, affords resistant oligosaccharides that provide a bottom-up analysis. Ovine enoxaparins and Lovenox were compared to one another using this approach ([Figure 5A and B](#fig5-1076029619840701){ref-type="fig"}).

![A and B, Comparison of the oligosaccharides generated from heparin-protein linkage region (bottom-up analysis). C, Composition of the daughters and Lovenox on terminal structure composition (top-down analysis). Error bars indicate sample variability (Linkage dp4: ΔUA-Gal-Gal-Xyl-*O*-Ser; Linkage dp4 ox: ΔUA-Gal-Gal-Xyl-*O*-Ser~OX~; Linkage dp6 SO~3~: ΔUA-GlcNAc-GlcA-Gal-Gal-Xyl-*O*-Ser; Linkage dp6 SO~3~ OX: ΔUA-GlcNAc-GlcA-Gal-Gal-Xyl-*O*-Ser~OX~;).](10.1177_1076029619840701-fig5){#fig5-1076029619840701}

Lovenox had a higher normalized abundance of linkage region oligosaccharide than did the ovine enoxaparins. The 1,6-anhydro at reducing end in ovine enoxaparin (30.7 ± 0.3%) was higher than Lovenox, 23.2 ± 0.7%, as determined by mass spectrometry ([Figures 3](#fig3-1076029619840701){ref-type="fig"} [](#fig4-1076029619840701){ref-type="fig"}--[5](#fig5-1076029619840701){ref-type="fig"}). The nonreducing end saturated oligosaccharides in ovine enoxaparins (25.6% ± 1.7%) was slightly higher in ovine enoxaparins than in Lovenox (20.6 ± 1.4%) and the unsaturated oligosaccharides of ovine enoxaparin (74.4 ± 1.7%) was lower than Lovenox (79.4 ± 1.4%; [Figure 5C](#fig5-1076029619840701){ref-type="fig"}). These differences were expected based on the lower MW of the ovine intestinal heparins.

Conclusion {#section18-1076029619840701}
==========

There is a clear need to develop new sources for heparin and LMWH to diversify the supply of these critical life-saving drugs. The current study examines ovine intestinal heparin and ovine enoxaparin as potential replacements for porcine intestinal heparin and porcine enoxaparin or Lovenox. Unfractionated ovine intestinal heparin, while having some compositional differences and MW differences from unfractionated porcine heparin, has a similar profile of in vitro anticoagulant activities. Ovine enoxaparins had similar MW and in vitro anticoagulant activities as Lovenox. Some disaccharide compositional, oligosaccharide composition at the reducing and nonreducing ends and intact chain compositional differences could be observed between porcine enoxaparin and ovine LMWH. The similarity of these ovine and porcine heparin products suggests that their preclinical evaluation and ultimately clinical assessment is warranted.

Supplemental Material {#section19-1076029619840701}
=====================

###### Supplemental Material, SI_figures - Comparison of Low-Molecular-Weight Heparins Prepared From Ovine Heparins With Enoxaparin
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